NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 4 August 2021 9:00am – 17:59pm

**Location:** Zoom video conference

## Attendees

Committee members present

1. Professor Amanda Adler (Chair) Present for all items
2. Dr Paul Arundel (Guest Chair) Present for items 1 to 5
3. Dr Sanjeev Patel (Vice Chair) Present for all items
4. Dr Carlo BertiPresent for all items
5. Dr Charles Crawley Present for all items
6. Ms Denise Bryceland Present for items 1 to 6.2
7. Mr Gabriel Rogers Present for all items
8. Professor Iolo Doull Present for items 1 to 7.3
9. Dr Laura Bojke Present for all items
10. Ms Maria Brezitski Present for items 1 to 6
11. Dr Mark Glover Present for all items
12. Dr Megan John Present for all items
13. Professor Nicky Welton Present for all items
14. Mr Nigel Westwood Present for all items
15. Mr Peter Wheatley Price Present for all items
16. Dr Rhiannon Owen Present for all items
17. Professor Sarah Wild Present for all items
18. Stephen Smith Present for all items
19. Mr Tony Wootton Present for items 1 to 7.3
20. Dr Veline L’Esperance Present for all items

NICE staff present

Henry Edwards, Associate Director Present for items 1 to 4 and 6 to 8

George Braileanu, Technical Analyst Present for items 1 to 4

George Millington, Technical Analyst Present for items 7 to 8

Eleanor Donegan, Technical Adviser Present for items 1 to 4

Heidi Livingstone, Senior Public Involvement Adviser Present for items 1 to 4.2, 5 to 5.2

Lucy Ingram, Administrator Present for items 1 to 4 and 6 to 8

Nick Cunningham, Coordinator Present for items 1 to 4.2, 6 to 6.2 and 7 to 7.2

Olivia Havercroft, Senior Medical Editor Present for items 1 to 4

Philip Williams, Finance/Business Analyst Present for all items

Shonagh D’Sylva, Project Manager Present for items 1 to 4 and 6 to 8

Sophie McHugh, Administrator Present for all items

Stevie Okoro, Technical Analyst Present for items 1 to 4

Nicole Elliott, Associate Director Present for items 5 to 6

Joanne Ekeledo, Project Manager Present for items 5 to 6

Emma Gordon, Administrator Present for items 5 to 6

Catherine Pank, Assistance Project Manager Present for items 5 to 6

Louise Jones, Administrator Present for items 5 to 6

Yelan Guo, Technical Adviser Present for items 5 to 6

Heather Stegenga, Technical Analyst Present for items 5 to 6

Korin Knight, Senior Digital Editor Present for items 5 to 6

Ella Livingstone, Technical adviser Present for all items

Rosalee Mason, Coordinator Present for all items 5 to 5.2

Ewa Rupniewska, Technical Adviser Present for items 6 to 8

Hannah Walker, Coordinator Present for items 6 to 7

Hayley Garnett, Senior Medical Editor Present for items 6 to 7

Helen Barnett, Senior Medical Editor Present for items 7 to 8

Rebecca Thomas, Technology Analyst Present for items 6 to 7

External group representatives present

Dr Graham Scotland, Reader in Health Economics, Aberdeen HTA Group Present for items 1 to 4.2

Dr Neil Scott, Medical Statistician, Aberdeen HTA Group Present for items 1 to 4.2

Sabine Grimm, Researcher, Kleijnen Systematic Reviews

Present for items 5 to 5.3

Robert Wolff, Managing Director, Kleijnen Systematic Reviews Present for items 5 to 5.3

Mubarak Patel, Research Associate, Statistician,

Warwick Evidence Present for items 6 to 6.3

Ewen Cummins, Health Economist, Warwick Evidence

Present for items 6 to 6.3

Dr Dwayne Boyers, Health Economist, Aberdeen HTA Group

Present for items 7 to 7.3

Dr Lorna Aucott, Senior Statistician, Aberdeen HTA Group

Present for items 7 to 7.3

Experts present

Professor Christopher Aldo Rinaldi, Consultant Cardiologist,

Guy’s & St Thomas’ Hospitals Present for items 1 to 4.2

Dr Andrew Turley, Consultant Cardiologist,

South Tees Hospitals NHS Foundation Trust Present for items 1 to 4.2

Dr Jonathan Sandoe, Associate Clinical Professor

Microbiology and Honorary Consultant Microbiologist,

University of Leeds Present for items 1 to 4.2

Mrs Trudie Lobban, Founder & CEO, AF Association Present for items 1 to 4.2

Prof. Richard Attanoos, Consultant Pathologist,

University Hospital of Wales Present for items 5 to 5.2

Dr Toby Talbot, Consultant Clinical Oncologist,

Royal Cornwall Hospitals Present for items 5 to 5.2

Mr Richard Lech, Patient with lived experience

nominated by Mesothelioma UK Present for items 5 to 5.2

Mrs Leah Taylor, Mesothelioma Clinical Nurse Specialist Present for items 5 to 5.2

Professor Peter Clark, Cancer Drugs Fund Lead Present for items 5 to 5.3 and 6 to 6.3

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Paul Arundel welcomed members of the committee and other attendees present to the meeting.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on **Wednesday 7 July 2021**

### Appraisal of [ID1440] TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices

* 1. Part 1 – Open session
     1. The chair, Dr Paul Arundel, welcomed the invited professional experts, external group representatives, members of the public and company representatives from Medtronic.
     2. The chair, Dr Paul Arundel asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Christopher Aldo Rinaldi declared an indirect interest as he receives research funding to undertake cardiac device research from Medtronic.

It was agreed that his declaration would not prevent Professor Christopher Aldo Rinaldi from providing expert advice to the committee.

* Dr Andrew Turley declared a direct – financial interest as he received payment from Medtronic for a speaking engagement (Heart Rhythm Congress 2017) and direct payment to attend a meeting to discuss innovations including TYRX (Medtronic, Minneapolis, October 2019).

It was agreed that his declaration would not prevent Dr Andrew Turley from providing expert advice to the committee.

* + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Henry Edwards and Professor Nicky Welton.
    2. The committee discussed confidential information submitted for this item.
  1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with its decisions.

### Appraisal of [ID1609] Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma)

* 1. Part 1 – Open session
     1. The chair, Professor Amanda Adlerwelcomed the invited professional experts, external group representatives, members of the public and company representatives from Bristol-Myers Squibb Pharmaceuticals.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Toby Talbot declared a Direct, Financial interest as he received fees from BMS for advisory board activity directly relating to the results from the Checkmate 743 trial, date of meeting Thursday 10th September 2020. Previous paid activities with BMS include delivering talks and teaching, advisory board meetings relevant to other tumour types (other than mesothelioma) and sponsorship to attend national and international meetings and conferences – multiple occurrences over last 10 years.

It was agreed that his declaration would not prevent Dr Toby Talbot from providing expert advice to the committee.

* Mrs Leah Taylor declared an indirect interest as she is funded by Mesothelioma UK, a UK wide charity that advocates for mesothelioma patients and is being nominated to represent Mesothelioma UK as an advocate. Mesothelioma UK is a charity which derives all of its funding by donations.

It was agreed that her declaration would not prevent Mrs Leah Taylor from providing expert advice to the committee.

* + 1. The chair, Professor Amanda Adler, led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Nicky Welton, Professor Iolo Doull and Mr Nigel Westwood.
  1. Part 2a – Closed session (members of the public, professional experts and company representatives were asked to leave the meeting. The evidence review group remained).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external group representatives and Professor Peter Clarke were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with its decisions.

### Appraisal of [ID1640] Prostate cancer (hormone relapsed, metastatic, treated) - olaparib

* 1. Part 1 – Open session
     1. The chair, Professor Amanda Adler, welcomed the invited professional experts, external group representatives, members of the public and company representatives from AstraZeneca UK Ltd
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting Mr Peter Wheatley Price declared a Financial Interest as Takeda manufacture leuprorelin which is a product used to treat prostate cancer in the hormone sensitive stage.
* It was agreed that his declaration would not prevent Mr Peter Wheatley Price from participating in this section of the meeting.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Amanda Adler, committee chair.
  1. Part 2a – Closed session (members of the public and the company representatives were asked to leave the meeting. The external group representatives remained).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (External group representatives and Professor Peter Clark were asked to leave the meeting).
  3. The committee asked the NICE technical team to prepare the documents in line with its decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10584>

### Appraisal of [ID1669] Psoriasis (plaque, moderate, severe, age 6-17) - secukinumab

* 1. Part 1 – Open session
     1. The chair, Dr Sanjeev Patel, welcomed the invited professional experts, external group representatives, members of the public and company representatives from Novartis Pharmaceuticals (UK) Ltd.
     2. The chair, Dr Sanjeev Patel, asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
     3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Henry Edwards.
  2. Part 2a – Closed session (members of the public and company representatives were asked to leave the meeting. The external representative group).
     1. The committee discussed confidential information submitted for this item.
  3. Part 2b – Closed session (company representatives, external group representatives and members of the public were asked to leave the meeting).

7.2.3 The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus. 7.3.2 The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with its decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 9 September 2021 and will start promptly at 9:00am.